Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis

Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. We analyzed data from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Menopause (New York, N.Y.) Ročník 25; číslo 6; s. 625
Hlavní autoři: Kattah, Andrea G, Suarez, Maria L G, Milic, Natasa, Kantarci, Kejal, Zeydan, Burcu, Mosley, Thomas, Turner, Stephen T, Ware, Erin B, Kardia, Sharon L R, Garovic, Vesna D
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.06.2018
ISSN:1530-0374, 1530-0374
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study. In the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04). HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
AbstractList Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study. In the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04). HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies.OBJECTIVEExperimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies.We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study.METHODSWe analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study.In the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04).RESULTSIn the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04).HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.CONCLUSIONSHT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
Author Suarez, Maria L G
Turner, Stephen T
Milic, Natasa
Mosley, Thomas
Kattah, Andrea G
Ware, Erin B
Kardia, Sharon L R
Kantarci, Kejal
Garovic, Vesna D
Zeydan, Burcu
Author_xml – sequence: 1
  givenname: Andrea G
  surname: Kattah
  fullname: Kattah, Andrea G
  organization: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
– sequence: 2
  givenname: Maria L G
  surname: Suarez
  fullname: Suarez, Maria L G
  organization: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
– sequence: 3
  givenname: Natasa
  surname: Milic
  fullname: Milic, Natasa
  organization: Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
– sequence: 4
  givenname: Kejal
  surname: Kantarci
  fullname: Kantarci, Kejal
  organization: Department of Neuroradiology, Mayo Clinic, Rochester, MN
– sequence: 5
  givenname: Burcu
  surname: Zeydan
  fullname: Zeydan, Burcu
  organization: Department of Neuroradiology, Mayo Clinic, Rochester, MN
– sequence: 6
  givenname: Thomas
  surname: Mosley
  fullname: Mosley, Thomas
  organization: Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi, Jackson, MS
– sequence: 7
  givenname: Stephen T
  surname: Turner
  fullname: Turner, Stephen T
  organization: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
– sequence: 8
  givenname: Erin B
  surname: Ware
  fullname: Ware, Erin B
  organization: Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI
– sequence: 9
  givenname: Sharon L R
  surname: Kardia
  fullname: Kardia, Sharon L R
  organization: Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI
– sequence: 10
  givenname: Vesna D
  surname: Garovic
  fullname: Garovic, Vesna D
  organization: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29381664$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LAzEQhoNU7If-A5EcPXRrvtxtvEmpVah40XOZJFMa2Y-aZNX99y5aoXOZ4eWZB2bGZFA3NRJyydmMM13crJ6XM3ZUnOXihIz4rWQZk4UaHM1DMo7xvYeEFsUZGQot5zzP1YhUj02oejFNOwyw7yjUjrbB98k-NAl9TfHbBky-qe8o0Kotkw9gPZTUNrsmJBpT67opjV1MWEHylgb89Pg1_XVVmCCDGsou-nhOTrdQRrw49Al5e1i-Lh6z9cvqaXG_zqwSQmRb7ubaKG4U00bPC6U4cGedsVoaAzYHMAZROQecgROM5UqgkNLIudsWUkzI9Z-3v-GjxZg2lY8WyxJqbNq44VrLfikXqkevDmhrKnSbffAVhG7z_yLxA4IZbTM
CitedBy_id crossref_primary_10_1097_GME_0000000000001111
crossref_primary_10_1007_s40620_020_00826_w
crossref_primary_10_1016_j_mayocp_2018_12_024
crossref_primary_10_1097_GME_0000000000001675
crossref_primary_10_1053_j_ajkd_2021_05_002
crossref_primary_10_1111_petr_14864
crossref_primary_10_2147_DMSO_S292041
crossref_primary_10_1097_MNH_0000000000000463
crossref_primary_10_1007_s40620_024_02099_z
crossref_primary_10_1038_s41598_019_44415_9
crossref_primary_10_1016_j_semnephrol_2022_04_004
crossref_primary_10_1016_j_maturitas_2024_108145
crossref_primary_10_2215_CJN_0000000642
crossref_primary_10_1016_j_kint_2025_02_021
crossref_primary_10_1097_GME_0000000000001579
crossref_primary_10_1053_j_ajkd_2024_01_522
crossref_primary_10_1172_JCI190850
crossref_primary_10_2215_CJN_0000000000000289
ContentType Journal Article
DBID NPM
7X8
DOI 10.1097/GME.0000000000001062
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1530-0374
ExternalDocumentID 29381664
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL087660
– fundername: NHLBI NIH HHS
  grantid: U10 HL054457
– fundername: NHLBI NIH HHS
  grantid: U01 HL054457
– fundername: NIA NIH HHS
  grantid: P50 AG044170
– fundername: NHLBI NIH HHS
  grantid: U10 HL054481
– fundername: NCATS NIH HHS
  grantid: UL1 TR000135
– fundername: NHLBI NIH HHS
  grantid: U10 HL054464
– fundername: NIA NIH HHS
  grantid: RF1 AG057547
– fundername: NHLBI NIH HHS
  grantid: U01 HL054481
– fundername: NHLBI NIH HHS
  grantid: U01 HL054464
GroupedDBID ---
-~X
.GJ
.XZ
.Z2
0R~
123
4Q1
4Q2
4Q3
53G
5RE
5VS
AAAAV
AAHPQ
AAIQE
AAJCS
AAMTA
AARTV
AASCR
AAWTL
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACDDN
ACEWG
ACGFS
ACILI
ACWDW
ACWRI
ACWUS
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AFBFQ
AFDTB
AFEXH
AFNMH
AHQNM
AHQVU
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BQLVK
BS7
C45
CS3
DIWNM
DUNZO
E.X
EBS
EEVPB
EJD
EX3
F5P
FCALG
FD6
FL-
GMYUL
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
L-C
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
ODMTH
OHYEH
OLG
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
ZFV
ZZMQN
7X8
ACBKD
ADKSD
ID FETCH-LOGICAL-c4222-f1d89b41b409b987441a1dcdbc93bbac6aabbee4dda10ad200642e233b38df732
IEDL.DBID 7X8
ISICitedReferencesCount 24
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000442313500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1530-0374
IngestDate Sun Nov 09 09:02:24 EST 2025
Mon Jul 21 05:55:00 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4222-f1d89b41b409b987441a1dcdbc93bbac6aabbee4dda10ad200642e233b38df732
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 29381664
PQID 1993006624
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1993006624
pubmed_primary_29381664
PublicationCentury 2000
PublicationDate 2018-06-00
20180601
PublicationDateYYYYMMDD 2018-06-01
PublicationDate_xml – month: 06
  year: 2018
  text: 2018-06-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Menopause (New York, N.Y.)
PublicationTitleAlternate Menopause
PublicationYear 2018
References 29664763 - Menopause. 2018 Jun;25(6):591-593
References_xml – reference: 29664763 - Menopause. 2018 Jun;25(6):591-593
SSID ssj0002927
Score 2.339165
SecondaryResourceType review_article
Snippet Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 625
Title Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/29381664
https://www.proquest.com/docview/1993006624
Volume 25
WOSCitedRecordID wos000442313500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uigjio77qixU8djHZLE3Wi4i09tLSg0JvYfYR6KFJbavov3cfKT0JgjnktiHZzM5--83MNwB31hkanrqTaieLKGeqoJmKOVUyMkZpnTHkvtlEOhxm47EY1YTbok6rXPlE76h1pRxHfu8SzbxcOX-cvVPXNcpFV-sWGpvQSCyUcVadjtdq4Uz4lq12UUfU6aysSudEev8y6AbpwvqyJyP2O8j0m03v4L-veQj7NcwkT8EujmDDlE3YGdSB9CbsBbqOhCqkY5j2LXatSkNCPdY3wVITR8Qb4pUcJiUxX8pVPFblA0Hi8xDn6Ph24nrszpfEC9W2yVoamoSymLZ_1tQskWKtgHICb73u63Of1p0YqHIUES1inQnJY2lPg1I4xfwYY620VCKRElUHUUpjuNYYR6gdTcGZYUkik0wXacJOYau0H3EOJE47dqz1G4pLjkyjUKIwFrXZTTLClLfgdjWxubV0F77A0lQfi3w9tS04C38nnwVJjtyCFhcA5Rd_GH0Juxb1ZCHf6woahV3n5hq21edyspjfeBOy9-Fo8AOBf9DJ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hormone+therapy+and+urine+protein+excretion%3A+a+multiracial+cohort+study%2C+systematic+review%2C+and+meta-analysis&rft.jtitle=Menopause+%28New+York%2C+N.Y.%29&rft.au=Kattah%2C+Andrea+G&rft.au=Suarez%2C+Maria+L+G&rft.au=Milic%2C+Natasa&rft.au=Kantarci%2C+Kejal&rft.date=2018-06-01&rft.issn=1530-0374&rft.eissn=1530-0374&rft.volume=25&rft.issue=6&rft.spage=625&rft_id=info:doi/10.1097%2FGME.0000000000001062&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-0374&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-0374&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-0374&client=summon